secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001193125-24-009293
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote lowers FY2023 revenue guidance to $185-187M; acquires Asteria Health for $8.5M
--------------------------------------------------------------------------------

- FY2023 revenue expected $185-187M (prior guidance $190-200M lower end); Adjusted EBITDA $54-56M (prior $56-60M).
- Q4 2023 revenue $45-47M; Adj. EBITDA $12-14M; nutraceutical revenue down ~15% due to distributor exit.
- FY2024 guidance: revenue >$200M, Adj. EBITDA >$60M; first half growth low-single digits, improving in H2.
- Acquired Asteria Health (503B manufacturer) for $8.5M cash + up to $0.5M earnout; close expected Q1 2024.
- Acquisition enables vertical integration of hormone product manufacturing and margin improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524009293/0001193125-24-009293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524009293/d730565d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-009293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer